Accordingly, we designed a series of in vivo and in vitro functional and molecular assays to explore how EIF4A3 overexpression mediates GBM development and concluded that EIF4A3 is a potential prognostic factor. This evidence concerns the gene EIF4A3 and glioblastoma.